A Phase 1/2 interventional study of PRA-216 and Placebo in Mild to Moderate Asthma, sponsored by Prana Therapies Inc. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Prana Therapies Inc · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 128 studies in Asthma with a site in Australia — 7 open to participants now, 12 under way, 5 of them phase 3. Asthma · Australia.
Among the 128 studies in Asthma with a site in Australia, this one is the 79th largest by planned enrollment of the 120 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 1/2, reaches primary completion later than 1 of the 11 other live ones, and was the 124th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →7 of the 128 studies in Asthma with a site in Australia are open now. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Australia, Canada, United Kingdom
Ages 18–79
Generate Biomedicines · Sites in Australia, United States, Argentina and 16 more countries
Ages 12–80
University of Melbourne · Sites in Australia
Ages 18–70 · Healthy volunteers
Windward Bio · Sites in Australia, United States, Argentina and 5 more countries
Ages 18–75
Helixon Biotechnology (Suzhou) Co., Ltd · Sites in Australia
Ages 18–55 · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
128 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 31 · Phase 3 49 · Phase 4 9
First in 2002; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 244 across the 120 interventional studies, 135 across the 6 observational. Of the 112 that completed or were terminated, 61 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
113 of 128 have an industry lead sponsor. The 10 most frequent:
Prana Therapies Inc is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Prana Therapies Inc has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
4 of the studies in Asthma with a site in Australia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT03667651Phase 3University of MelbourneThe PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants | 2027-05-31 |
| NCT06637371AmgenA Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma | 2027-04-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 128 studies in Asthma with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 1 of this study will consist of 2 parts
Phase 2a of this study is a randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and immunogenicity of PRA-216 in participants with mild to moderate asthma. The dose of PRA-216 for this phase was determined from Phase 1.
This study is a Phase 1/2a randomized, double-blind, placebo-controlled, single- and multiple-dose study with staggered dose escalations in healthy participants and participants with mild to moderate asthma. Single-ascending dose (SAD) cohorts will be evaluated for one single dose administered. Multiple ascending dose (MAD) cohorts will be evaluated for repeat doses .
Participants with mild to moderate asthma will be recruited for Phase 2a of this study, to evaluate safety of randomized, double blind, placebo controlled PRA-216. The dose of PRA-216 for this phase was determined from Phase 1 safety, tolerability, and PK data. Additional dose levels or schedules may be used for Phase 2a, depending on data from Phase 1.
This study consists of 2 phases, as follows:
Phase 1, Part 1:
SAD in healthy volunteers. Study visits in this section will entail a single dose administration of PRA-216 or placebo and collection of study data.
Phase 1, Part 2:
MAD in healthy volunteers. Study visits in this section will entail repeat doses of PRA-216 or placebo and collection of study data.
Phase 2a Participants with mild to moderate asthma will receive PRA-216 or placebo.
Phase 1
Inclusion Criteria:
Exclusion Criteria:
Phase 2a
Inclusion criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy volunteers will receive a single dose of PRA-216 in a dose escalation format.
Drug: PRA-216
Healthy volunteers will receive a single dose of placebo
Drug: Placebo
Healthy volunteers will receive repeated doses of PRA-216 in a dose escalation format.
Drug: PRA-216
Healthy volunteers will receive repeated doses of placebo comparator.
Drug: Placebo
Participants with mild to moderate asthma will be randomized to receive repeat doses of PRA-216.
Drug: PRA-216
Participants with mild to moderate asthma will be randomized to receive repeat doses of placebo.
Drug: Placebo
biologic
matching placebo for PRA-216
Phase 1: Incidence, nature, and severity of serious adverse events (SAEs) with a single dose of PRA-216 in healthy volunteers (SAD arm)
Incidence, nature, and severity of serious adverse events (SAEs)
Time frame: Up to Study Day 169
Phase 1: Incidence, nature, and severity of serious adverse events (SAEs) of multiple doses of PRA-216 in healthy volunteers (MAD arm)
Incidence, nature, and severity of and serious adverse events (SAEs)
Time frame: up to Study Day 169
Phase 2a: To evaluate the effect of multiple doses of PRA-216 compared to placebo on exhaled nitric oxide (FeNO) in asthma participants
Fractional exhaled nitric oxide (FeNO) is a non-invasive biomarker of airway inflammation in asthma.
Time frame: Up to Study Day 57
Phase 1: Immunogenicity of PRA-216: ADA in healthy volunteers
Incidence and magnitude of anti-drug antibody following single or multiple doses of PRA-216
Time frame: Up to Study Day 169
Phase 1: Pharmacokinetics of PRA-216: Tmax in healthy volunteers
Time to maximum concentration of drug in plasma following single or multiple doses of PRA-216
Time frame: Up to Study Day 169
Phase 1: Pharmacokinetics of PRA-216: AUC in healthy volunteers
Area under the curve following single or multiple doses of PRA-216
Time frame: Up to Study Day 169
Phase 1: Pharmacokinetics of PRA-216: Cmax in healthy volunteers
Maximum concentration of PRA-216 in plasma following single or multiple doses of PRA-216.
Time frame: Up to Study Day 169
Phase 2a: Incidence, nature, and severity of serious adverse events (SAEs) of PRA-216 in patients with asthma
Incidence, nature, and severity of serious adverse events (SAEs)
Time frame: Up to Study Day 197
Phase 2a: Immunogenicity of PRA-216: ADA in patients with asthma
Incidence and magnitude of anti-drug antibody following drug administration
Time frame: Up to Study Day 197
Phase 2a: Pharmacokinetics of PRA-216: Tmax in patients with asthma
Time to maximum concentration of drug in plasma following multiple doses of PRA-216
Time frame: Up to Study Day 197
Phase 2a: Pharmacokinetics of PRA-216: AUC in patients with asthma
Area under the curve of PRA-216 following multiple doses of PRA-216
Time frame: Up to Study Day 197
Phase 2a: Pharmacokinetics of PRA-216: Cmax in patients with asthma
Maximum concentration in plasma of PRA-216 following multiple doses
Time frame: Up to Study Day 197
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Oct 2026, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prana Therapies Inc